M
SPRO icon

Murchinson’s Spero Therapeutics SPRO Stock Holding History

Murchinson’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-873,910
Closed -$629K – 100
2025
Q1 		$629K Hold
873,910
– – 0.03% 64
2024
Q4 		$900K Buy
+873,910
New +$1.04M 0.39% 32
2024
Q3 		– Sell
-873,910
Closed -$1.14M – 109
2024
Q2 		$1.14M Hold
873,910
– – 0.18% 47
2024
Q1 		$1.5M Buy
873,910
+11,210
+1% +$17.6K 0.13% 55
2023
Q4 		$1.27M Hold
862,700
– – 0.22% 30
2023
Q3 		$1.04M Buy
862,700
+100,000
+13% +$139K 0.13% 35
2023
Q2 		$1.11M Sell
762,700
-42,921
-5% -$73.5K 0.14% 26
2023
Q1 		$1.11M Buy
805,621
+42,921
+6% +$71.8K 0.16% 24
2022
Q4 		$1.32M Hold
762,700
– – 0.17% 25
2022
Q3 		$1.52M Buy
+762,700
New +$758K 0.44% 25

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Murchinson's SPRO Position: Q2 2025 in Review

Murchinson sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 873,910 shares — an estimated $629K sold.

Murchinson first reported a position in SPRO in Q3 2022 and held it in 10 quarters. The position peaked at $1.52M in Q3 2022. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

  • Murchinson reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Murchinson sold 873,910 Spero Therapeutics shares in Q2 2025, an estimated $629K.
  • Murchinson first reported a position in Spero Therapeutics in Q3 2022 and held it in 10 quarters.
  • Murchinson's Spero Therapeutics position peaked at $1.52M in Q3 2022.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on Murchinson's 13F filing for Q2 2025, filed 14 Aug 2025.